The C-reactive protein to albumin ratio is an excellent prognostic predictor for gallbladder cancer

Bao, Yongjin; Duan, Yunfei; Chen, Yuxiang; Chen, Weibo; Sun, Donglin

doi:10.5582/bst.2020.03326

Cited by 22 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio was originally suggested to forecast the prognosis of acute hospitalized patients ( 7 ). Recently, various centers have explored the application of CAR as a prognostic biomarker for kinds of cancers, including gastric cancer ( 8 ), colorectal cancer ( 9 ), non-small-cell lung cancer ( 10 ), gallbladder cancer ( 11 ), etc. As for urinary neoplasms, a lot of studies have examined the prognostic value of CAR in RCC.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis

Zhou²,

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTo investigate the potential prognostic role of C-reactive protein to albumin ratio (CAR) in patients with urinary cancers, including renal cell carcinoma (RCC), bladder cancer (BC), and prostate cancer (PC).MethodsWe searched and screened literatures with PubMed, Embase, Cochrane Library, and Web of Science in January 2022. We applied combined hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the associations.ResultsThirteen studies including 2,941 cases were analyzed in our study. Merged results indicated that highly pretreated CAR was associated with inferior overall survival (HR 2.21, 95% CI 1.86-2.62, p < 0.001) and progression-free survival (HR 1.85, 95% CI 1.36-2.52, p < 0.001) for urinary cancers. In a subgroup analysis of OS by tumor type, CAR can be a predictor in RCC (HR 2.10, 95% CI 1.72-2.56), BC (HR 3.35, 95% CI 1.94-5.80), and PC (HR 2.20, 95% CI 1.43-3.37). In a subgroup analysis of PFS by tumor type, CAR can be a predictor in BC (HR 1.76, 95% CI 1.03-3.02), and RCC (HR 1.90, 95% CI 1.25-2.89). The reliability and robustness of results were confirmed.ConclusionsHigh pretreated CAR was effective predictor of poor survival in patients with urinary cancers and can act as prognostic factor for these cases.Systematic Review RegistrationPROSPERO (CRD42022306414).

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis

Zhou²,

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Multiple studies have demonstrated that some ratios and scores based on peripheral inflammatory cells, including NLR, PLR, LMR, Hs-mGPS, CAR, and SII, have been identified as prognostic biomarkers in various solid malignancies such as lung cancer, osteosarcoma, and gallbladder cancer. 22 – 25 NLR, PLR, LMR, Hs-mGPS, SII, and CAR are the prevailing inflammation prognostic biomarkers based on routine blood examinations, which can be widely available without additional costs. 22 , 26 , 27 According to the ratio or combination of inflammatory immune and nutritional factors, these inflammation biomarkers may be more valuable.…”

Section: Discussionmentioning

confidence: 99%

“…28 Bao et al verified that CAR was a risk factor for poor prognosis, together with clinicopathological parameters in gallbladder cancer. 25 In addition, the systemic inflammatory response was correlated with the prognosis of pediatric solid tumors, but relatively fewer reports than in adults. 9,29 Several studies have revealed that inflammatory cytokines play important roles in pediatric solid tumors.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of the advanced lung cancer inflammation index (ALI) for patients with neuroblastoma

Zhou

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Objective The advanced lung cancer inflammation index (ALI) can predict the survival of patients with lung cancer and other malignancies. However, the prognostic significance of ALI in neuroblastoma has not been reported. This study aimed to evaluate the correlation between ALI and neuroblastoma patient prognosis. Methods We retrospectively analyzed the data of 72 neuroblastoma patients treated between January 2014 and August 2020. ALI calculation: Body mass index (BMI) × serum albumin (ALB)/neutrophil-to-lymphocyte ratio (NLR). The optimal cutoff points of prognostic biomarkers were determined by generating receiver operating characteristic (ROC) curves. According to the cutoff value, the patients were categorized into low or high ALI groups. The chi-square test was used to compare clinical parameters between the two groups. Potential prognostic factors associated with overall survival (OS) were assessed using Kaplan–Meier and Cox regression analyses. Results The optimal cutoff value of ALI was 49.17. The low ALI group showed more severe clinical characteristics and poorer survival rates. Univariate and multivariate Cox analyses suggested that ALI and the International Neuroblastoma Staging System (INSS) stage were independent prognostic factors for neuroblastoma patients. Conclusions Low ALI is associated with poor prognosis in neuroblastoma patients. ALI may be an independent prognostic biomarker for neuroblastoma.

show abstract

“…Recently, the CAR has been highlighted as a predictor of poor prognosis in various clinical conditions, including atherosclerotic disease and cancer. 11,12,38,39 A recent study showed that PAD patients in the high-CAR group based on a cut-off median value had a higher incidence of all-cause death and amputation after undergoing EVT. 35 Our study also showed similar results, indicating that CAR has a significant impact on predicting lesion complexity and future clinical outcomes in PAD patients treated with EVT.…”

Section: Discussionmentioning

confidence: 99%

Elevated C-Reactive Protein/Albumin Ratio Is Associated With Lesion Complexity, Multilevel Involvement, and Adverse Outcomes in Patients With Peripheral Artery Disease

et al. 2022

View full text Add to dashboard Cite

Inflammation plays an important role in the progression of peripheral artery disease (PAD). We investigated the predictive value of the C-reactive protein-to-albumin ratio (CAR) on the severity of PAD and outcomes after endovascular therapy (EVT). Patients (n = 307) with PAD who underwent EVT were retrospectively reviewed and categorized according to CAR tertiles. The groups were compared for the prevalence of complex lesions and multilevel involvement as well as the incidence of major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs). The rates of complex lesions and multilevel involvement increased with increasing CAR tertiles (all P < .001). These associations remained significant even after adjustment for other confounders (complex lesion odds ratio, 1.22 [1.03-1.50]; P = .036; multilevel disease odds ratio, 1.20 [1.01-1.44]; P = .041). The third CAR tertile showed a significantly higher incidence of MACEs and MALEs than the second and first tertiles within a year (log-rank P < .001). A higher CAR as a continuous variable was also independently associated with the 4-year rate of MACE (hazard ratio, 1.20 [1.04-1.38]; P = .015). Elevated CAR was a powerful surrogate marker of severe PAD and worse outcomes. Thus, CAR might become a predictor of poor prognosis in patients with PAD.

show abstract

The C-reactive protein to albumin ratio is an excellent prognostic predictor for gallbladder cancer

Cited by 22 publications

References 34 publications

Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis

Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis

The prognostic value of the advanced lung cancer inflammation index (ALI) for patients with neuroblastoma

Elevated C-Reactive Protein/Albumin Ratio Is Associated With Lesion Complexity, Multilevel Involvement, and Adverse Outcomes in Patients With Peripheral Artery Disease

Contact Info

Product

Resources

About